Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with or without interferon-alpha in hepatitis B virus-related hepatocellular carcinoma
ISRCTN85736336Phase 4Completed
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Dec 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon alfa, epirubicin and ethiodized oil in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: HBV reactivation, Hepatitis due to HBV reactivation and 2 more. Started Dec 2008; status: completed.
02
Drugs
interferon alfaepirubicinethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ISRCTN85736336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85736336.